Chimeric Therapeutics

ChimericModel CHM 1301 (CLTX CAR NK) -NK Cell Derived Allogeneic Therapies

SHARE

CHM 1301 (CLTX CAR NK) will be developed on the next generation CORE-NK platform leveraging our CLTX Chimeric Antigen Receptor.